According to preclinical data, a combination therapy consisting of erlotinib and cisplatin targets angiogenesis and manifests synergistic and additive antitumor activity via downregulation of the c-MYC–HIF-1α–VEGF signaling pathway in mutated NSCLC with exon 19 deletions (Figure 1) [32–34]. The gene discussed is VEGFA; the disease is non-small cell lung carcinoma.